InSyBio
InSyBio helps researchers and companies discover predictive biomarkers and personalized treatment or nutrition models from complex biological data. The company delivers a SaaS and services platform, InSyBio Suite, combining bioinformatics pipelines (DNASeq, ncRNASeq), interactomics and proteomics analyses with AI and machine learning models to extract integrated multi-omics biosignatures. Their offering includes modular tools (BioNets, Interact, Datastore, Pipelines, Biomarkers) and licensing for preclinical and clinical studies, diagnostics, and personalization tests for nutrition and cosmetics firms. InSyBio serves academic researchers, pharmaceutical companies, and the nutrition/cosmetics industry to accelerate biomarker discovery, reduce analysis time and costs, and improve predictive accuracy in low-sample studies.
InSyBio
InSyBio helps researchers and companies discover predictive biomarkers and personalized treatment or nutrition models from complex biological data. The company delivers a SaaS and services platform, InSyBio Suite, combining bioinformatics pipelines (DNASeq, ncRNASeq), interactomics and proteomics analyses with AI and machine learning models to extract integrated multi-omics biosignatures. Their offering includes modular tools (BioNets, Interact, Datastore, Pipelines, Biomarkers) and licensing for preclinical and clinical studies, diagnostics, and personalization tests for nutrition and cosmetics firms. InSyBio serves academic researchers, pharmaceutical companies, and the nutrition/cosmetics industry to accelerate biomarker discovery, reduce analysis time and costs, and improve predictive accuracy in low-sample studies.
TL;DR
Founded: 2013
Product: InSyBio Suite — cloud SaaS for multi-omics biomarker discovery
Customers: Academic researchers, pharma, nutrition and cosmetics companies
Latest funding: Series A announced Jul 1, 2023 (lead: Loyal VC)
Company Overview
Problem Domain
Biomarker discovery and predictive analytics for precision medicine, clinical trials, precision nutrition, and cosmetics personalization.
Founded
2013
Industry
Biotechnology
Tech Stack
Funding Track Record
Announced as latest round; company communications describe Loyal VC program participation and follow-on funding in 2021–2023.
Investor Signal
“Loyal VC, NBG Business Seeds, National Bank of Greece”